Question 1

What is the difference between Ozempic and Wegovy?

Accepted Answer

Ozempic and Wegovy are the same molecule — semaglutide — made by the same company, Novo Nordisk. What differs is the FDA label and the dose range. Ozempic is approved for type 2 diabetes and for lowering heart attack and stroke risk in people with diabetes and existing heart disease. Its dose tops out at 2 mg weekly. Wegovy is approved for chronic weight management in adults and teens and, since March 2024, for reducing major cardiovascular events in adults with heart disease and obesity or overweight. Wegovy's maintenance dose is 2.4 mg weekly, and Wegovy HD reaches 7.2 mg. Both are once-weekly subcutaneous injections.

Question 2

Which causes more weight loss, Ozempic or Wegovy?

Accepted Answer

Wegovy produces more weight loss, mostly because its doses are higher. In STEP 1, adults on Wegovy 2.4 mg weekly lost roughly 16.9% of baseline body weight over 68 weeks. Ozempic was not studied as a weight-loss drug — it is approved for diabetes — but in the SUSTAIN diabetes trials, patients on 1 mg weekly typically lost 4 to 6 kg, and meaningfully more on 2 mg. The gap is mostly a dose story. At matched milligrams, the molecule behaves the same way. If weight management is the goal, Wegovy's label and higher dose range make it the appropriate choice. Individual results vary with adherence and lifestyle.

Question 3

Can I switch between Ozempic and Wegovy?

Accepted Answer

Yes, and because both are semaglutide, the clinical switch is simple — no washout is medically required. The catch is insurance and diagnosis. Your prescription has to match your label: Ozempic for diabetes, Wegovy for weight management or heart-event prevention. If you have both diabetes and obesity, your prescriber can pick either label based on which indication drives your coverage. Doses do not translate one-to-one across products — maximum Ozempic is 2 mg, maximum Wegovy is 2.4 mg (standard) or 7.2 mg (HD), and titration schedules differ. Your prescriber sets the starting dose of the new product based on your current dose and tolerability. Expect paperwork for prior authorization.

Question 4

Which has fewer side effects, Ozempic or Wegovy?

Accepted Answer

The side effects are the same family because the drug is the same — the difference is how hard the dose is pushed. Ozempic's diabetes-trial rates run lower: nausea 15 to 20%, vomiting 5 to 9%, diarrhea 8 to 12%. Wegovy's obesity-trial rates run higher because the dose is higher: nausea around 44%, vomiting 24%, diarrhea 30% in STEP 1. At equal milligrams in equal patients, tolerability would be equal too. Both carry the thyroid-tumor boxed warning and the same pancreatitis and gallbladder risks. Slow titration at each dose step helps on either product. How you tolerate semaglutide has more to do with your own biology than which label is on the pen.

Question 5

Is Ozempic or Wegovy cheaper?

Accepted Answer

Sticker prices are similar because the drug is identical. What you actually pay depends almost entirely on insurance and what diagnosis is on the prescription. Ozempic is widely covered by commercial plans and Medicare Part D for type 2 diabetes, with typical preferred-tier copays of $25 to $150 after prior authorization. Wegovy coverage is patchier because many plans exclude weight-loss medications; the March 2024 cardiovascular indication opened some coverage for patients with heart disease. Medicare Part D does not cover Wegovy for weight loss alone under current federal law. Both manufacturers run savings cards for commercial patients. Confirm your plan's formulary before filling.

Question 6

Are Ozempic and Wegovy the same drug?

Accepted Answer

Chemically, yes — both contain semaglutide and come from Novo Nordisk. Legally and from an insurance perspective, no. They are separate FDA approvals with distinct prescribing information, separate dose ranges, and separate formulary treatment. Your pharmacy cannot substitute one for the other even though a chemist would call them the same drug. The label that appears on your prescription controls whether your plan pays for it. That is why a patient on Ozempic for diabetes cannot simply swap in a Wegovy pen at the pharmacy, and why someone using Wegovy for weight loss cannot renew it as Ozempic to dodge a coverage denial.

Question 7

Why are the same molecule sold as two separate drugs?

Accepted Answer

Novo Nordisk uses separate brands to match separate FDA indications, which is standard for the GLP-1 class — Eli Lilly does the same with Mounjaro (diabetes) and Zepbound (weight loss), both containing tirzepatide. Each label required its own clinical program: SUSTAIN for Ozempic's diabetes approval, STEP for Wegovy's obesity approval, SELECT for Wegovy's cardiovascular approval. Separate brands also allow different dose ranges, different packaging, different pricing, and different insurance pathways. For patients, the practical takeaway is that the molecule is one thing but the brand on the pen reflects the approved use — not any difference in the drug substance itself.

Question 8

If I'm on Ozempic for diabetes and want weight loss, should I switch to Wegovy?

Accepted Answer

Not necessarily, and the answer depends on your full picture. Ozempic already produces some weight loss as a secondary effect, and many patients with type 2 diabetes reach both glucose and weight goals on Ozempic alone. If you need more weight loss than Ozempic is producing, switching to Wegovy makes sense because its 2.4 mg maintenance dose and dedicated obesity label were designed for that. Coverage also matters — you likely need diabetes to keep Ozempic's insurance benefit, while Wegovy may require obesity-specific documentation. Taking both is not recommended because they are the same molecule. Your prescriber can help weigh the switch against other options like Zepbound.

Question 9

Do insurance companies treat Ozempic and Wegovy differently?

Accepted Answer

Yes, and this is often the biggest practical difference between the two. Ozempic prescriptions usually flow through standard pharmacy benefits for diabetes, with prior authorization but broad coverage. Wegovy prescriptions flow through weight-management benefits — a much narrower category that many plans exclude entirely. Employers choose whether to add obesity coverage as a rider, so two patients with the same insurance company can have different Wegovy access based on employer choices. Medicare Part D currently covers Ozempic for diabetes but not Wegovy for weight loss. The March 2024 cardiovascular indication for Wegovy helps some patients with heart disease get coverage. Always check your specific plan.

Feature	Ozempic(semaglutide)	Wegovy(semaglutide)
Active Ingredient	semaglutide	semaglutide
Drug Class	GLP-1 receptor agonist	GLP-1 receptor agonist
Manufacturer	Novo Nordisk	Novo Nordisk
FDA Approved	2017-12-05	2021-06-04
Approved Indications	Type 2 diabetes mellitus (adjunct to diet and exercise) Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease	Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity Chronic weight management in patients aged 12+ with BMI at 95th percentile or greater Reduction of risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) in adults with established CVD and either obesity or overweight (March 8, 2024)
Route	subcutaneous injection	subcutaneous injection
Frequency	Once weekly	Once weekly
Starting Dose	0.25 mg weekly	0.25 mg weekly
Maintenance Dose	0.5 mg or 1 mg weekly	2.4 mg weekly
Max Dose	2 mg weekly	7.2 mg weekly (Wegovy HD, approved March 19, 2026)
Weight Loss (%)	14.9%	16.9%
A1C Reduction	1.8%	N/A (not indicated for diabetes)
Key Trial	SUSTAIN 6 / STEP 5 (off-label weight) (104 weeks)	STEP 1 (68 weeks)
List Price	$935-$1,029/month	$1,349-$1,650/month
With Insurance	$25-$150/month (varies by plan)	$25-$250/month (varies by plan; many plans exclude weight-loss drugs)
Savings Card	$25/month (Novo Nordisk savings card, commercially insured)	$0/month for eligible patients (NovoCare savings program)

Side Effect	Ozempic	Wegovy
Nausea	15-20%	44%
Vomiting	5-9%	24%
Diarrhea	8-12%	30%
Constipation	3-6%	24%
Abdominal pain	6-11%	20%
Injection site reaction	0.2%	Not reported
Pancreatitis (rare)	<0.5%	<1%
Headache	Not reported	14%
Fatigue	Not reported	11%
Gallbladder events	Not reported	2.6%

Ozempic vs Wegovy: Same Semaglutide, Different FDA Labels

Summary

Ozempic vs Wegovy: Full Comparison

Side Effects: Ozempic vs Wegovy

Related Comparisons

Frequently Asked Questions

Sources & References

FDA & Regulatory

Clinical Trial Records

Peer-Reviewed Literature

Safety Communications

Manufacturer Information

Professional Guidelines

Reference Entries

Additional References